Your browser doesn't support javascript.
Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection.
Emerg Infect Dis ; 24(2): 328-335, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29350154
ABSTRACT
High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.
Assuntos

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Macrolídeos / Pristinamicina / Mycoplasma genitalium / Antibacterianos / Infecções por Mycoplasma Aspecto clínico: Terapia Limite: Adulto / Feminino / Humanos / Masculino Idioma: Inglês Revista: Emerg Infect Dis Assunto da revista: Doenças Transmissíveis Ano de publicação: 2018 Tipo de documento: Artigo